de Jong LA - Search Results

1

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.

Quist SW, de Jong LA, van Asten F, Knoester P, Postma MJ, Freriks RD. Quist SW, et al. Among authors: de jong la. Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1083-1095. doi: 10.1007/s00417-021-05359-x. Epub 2021 Oct 13. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 34643793 Free PMC article.

2

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.

Stevanović J, de Jong LA, Kappelhoff BS, Dvortsin EP, Voorhaar M, Postma MJ. Stevanović J, et al. Among authors: de jong la. PLoS One. 2016 Oct 24;11(10):e0163550. doi: 10.1371/journal.pone.0163550. eCollection 2016. PLoS One. 2016. PMID: 27776137 Free PMC article.

3

Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.

de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. de Jong LA, et al. Clin Ther. 2017 Feb;39(2):288-302.e4. doi: 10.1016/j.clinthera.2016.12.012. Epub 2017 Jan 28. Clin Ther. 2017. PMID: 28139289

4

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.

Jacobs MS, de Jong LA, Postma MJ, Tieleman RG, van Hulst M. Jacobs MS, et al. Among authors: de jong la. Eur J Health Econ. 2018 Sep;19(7):957-965. doi: 10.1007/s10198-017-0942-2. Epub 2017 Nov 27. Eur J Health Econ. 2018. PMID: 29181817 Free PMC article.

5

Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference.

de Jong LA, Koops M, Gout-Zwart JJ, Beinema MJ, Hemels MEW, Postma MJ, Brouwers JRBJ. de Jong LA, et al. Neth J Med. 2018 Dec;76(10):426-430. Neth J Med. 2018. PMID: 30569888 Free article. Review.

6

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.

de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ. de Jong LA, et al. J Med Econ. 2019 Apr;22(4):306-318. doi: 10.1080/13696998.2018.1563404. Epub 2019 Jan 15. J Med Econ. 2019. PMID: 30614320 Free article.

7

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects.

de Jong LA, Gout-Zwart JJ, Stevanovic J, Rila H, Koops M, Huisman MV, Postma MJ. de Jong LA, et al. TH Open. 2018 Sep 26;2(3):e315-e324. doi: 10.1055/s-0038-1672185. eCollection 2018 Jul. TH Open. 2018. PMID: 31249955 Free PMC article.

8

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, Postma MJ, van Hulst M. de Jong LA, et al. PLoS One. 2019 Sep 17;14(9):e0222658. doi: 10.1371/journal.pone.0222658. eCollection 2019. PLoS One. 2019. PMID: 31527894 Free PMC article.

9

Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands.

Gout-Zwart JJ, de Jong LA, Saptenno L, Postma MJ. Gout-Zwart JJ, et al. Among authors: de jong la. Pharmacoecon Open. 2020 Jun;4(2):321-330. doi: 10.1007/s41669-019-00179-6. Pharmacoecon Open. 2020. PMID: 31535305 Free PMC article.

10

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.

van der Pol S, de Jong LA, Vemer P, Jansen DEMC, Postma MJ. van der Pol S, et al. Among authors: de jong la. Value Health. 2019 Oct;22(10):1119-1127. doi: 10.1016/j.jval.2019.06.007. Epub 2019 Aug 6. Value Health. 2019. PMID: 31563254 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters